methyl 5-bromo-3-(bromomethyl)thiophene-2-carboxylate | 956118-39-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: methyl 5-bromo-3-(bromomethyl)thiophene-2-carboxylate
• CAS: 956118-39-1
• 化学式: C₇H₆Br₂O₂S
• 分子量: 313.997
• InChiKey: JOKWYUPQYGBOCM-UHFFFAOYSA-N

物化性质

• 沸点：
  358.7±42.0 °C(Predicted)
• 密度：
  1.932±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  54.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl 5-bromo-3-(bromomethyl)thiophene-2-carboxylate 在 四(三苯基膦)钯 、 水 、 potassium carbonate 、 1-羟基苯并三唑 、 caesium carbonate 、 三乙胺 、 sodium hydroxide 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 二氯甲烷 、 水 、 乙腈 为溶剂， 反应 18.5h， 生成 5-[(2R,3R)-3-(2,4-difluorophenyl)-3-hydroxy-4-(1H-1,2,4-triazol-1-yl)butan-2-yl]-2-(4-methylphenyl)-5,6-dihydro-4H-thieno[3,2-c]pyrrol-4-one
  参考文献：
  名称：

  Design, synthesis, and structure–activity relationship studies of novel thienopyrrolidone derivatives with strong antifungal activity against Aspergillus fumigates

  摘要：

  In order to further enhance the anti-Aspergillus efficacy of our previously discovered antifungal lead compounds (I), two series of novel azoles featuring thieno[2,3-c]pyrrolidone and thieno[3,2-clpyrroli-done nuclei were designed and evaluated for their in vitro activity on the basis of the binding mode of albaconazole using molecular docking, along with SARs of antifungal triazoles. Most of target compounds exhibited excellent activity against Candida and Cryptococcus spp., with MIC values in the range of 0.0625 mu g/ml to 0.0156 mu g/ml. The thieno[3,2-c]pyrrolidone unit was more suited for improving activity against Aspergillus spp. The most potent compound, 18a, was selected for further development due to its significant in vitro activity against Aspergillus spp. (MIC = 0.25 mu g/ml), as well as its high metabolic stability in human liver microsomes. (C) 2015 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2015.08.023
• 作为产物：
  描述：

  5-溴-3-甲基噻吩-2-甲酸 在 N-溴代丁二酰亚胺(NBS) 、 硫酸 、 过氧化苯甲酰 作用下， 以 四氯化碳 为溶剂， 反应 16.0h， 生成 methyl 5-bromo-3-(bromomethyl)thiophene-2-carboxylate
  参考文献：
  名称：

  Design, synthesis, and structure–activity relationship studies of novel thienopyrrolidone derivatives with strong antifungal activity against Aspergillus fumigates

  摘要：

  In order to further enhance the anti-Aspergillus efficacy of our previously discovered antifungal lead compounds (I), two series of novel azoles featuring thieno[2,3-c]pyrrolidone and thieno[3,2-clpyrroli-done nuclei were designed and evaluated for their in vitro activity on the basis of the binding mode of albaconazole using molecular docking, along with SARs of antifungal triazoles. Most of target compounds exhibited excellent activity against Candida and Cryptococcus spp., with MIC values in the range of 0.0625 mu g/ml to 0.0156 mu g/ml. The thieno[3,2-c]pyrrolidone unit was more suited for improving activity against Aspergillus spp. The most potent compound, 18a, was selected for further development due to its significant in vitro activity against Aspergillus spp. (MIC = 0.25 mu g/ml), as well as its high metabolic stability in human liver microsomes. (C) 2015 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2015.08.023

文献信息

• [EN] ANTIBACTERIAL ANNULATED PYRROLIDIN-2-ONE DERIVATIVES<br/>[FR] DÉRIVÉS DE PYRROLIDIN-2-ONE ANNELÉS ANTIBACTÉRIENS
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2017036968A1

  公开（公告）日：2017-03-09

  The invention relates to antibacterial compounds of formula I wherein X represents sulphur or CH=CH; R1 represents H, PO3H2, SO3H, phosphonooxymethyl or the group -CO-R2 wherein R2 is as defined in the claims M is one of the groups MA and MB represented below wherein A represents a bond or C≡C and R1A, R2A, R3A and R1B are as defined in the claims; and to salts thereof.

  该发明涉及公式I的抗菌化合物，其中X代表硫或CH=CH；R1代表H、PO3H2、SO3H、磷酸氧甲基或基团-CO-R2，其中R2如权利要求中所定义；M是下面表示的MA和MB中的一种，其中A代表键或C≡C，而R1A、R2A、R3A和R1B如权利要求中所定义；以及其盐。
• COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF
  申请人：BioTheryX, Inc.

  公开号：US20180170948A1

  公开（公告）日：2018-06-21

  The present invention provides compounds that modulate protein function, to restore protein homeostasis, including cytokine, CK1α, GSPT1, aiolos, and/or ikaros activity, and cell-cell adhesion. The invention provides methods of modulating protein-mediated diseases, such as cytokine-mediated diseases, disorders, conditions, or responses. Compositions, including in combination with other cytokine and inflammatory mediators, are provided. Methods of treatment, amelioration, or prevention of diseases, disorders, or conditions associated with a protein, such as diseases, disorders, and conditions associated with cytokines, including inflammation, fibromyalgia, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, inflammatory bowel diseases, Crohn's disease, ulcerative colitis, uveitis, inflammatory lung diseases, chronic obstructive pulmonary disease, Alzheimer's disease, and cancer, are provided.

  本发明提供了调节蛋白功能的化合物，以恢复蛋白稳态，包括细胞因子、CK1α、GSPT1、艾奥洛斯和/或伊卡洛斯活性和细胞间粘附。该发明提供了一种调节蛋白介导的疾病的方法，如细胞因子介导的疾病、障碍、状况或反应。提供了包括与其他细胞因子和炎症介质结合的组合物。提供了治疗、改善或预防与蛋白相关的疾病、障碍或状况的方法，包括与细胞因子相关的疾病、障碍和状况，包括炎症、纤维肌痛、类风湿性关节炎、骨关节炎、强直性脊柱炎、银屑病、银屑病关节炎、炎症性肠病、克罗恩病、溃疡性结肠炎、葡萄膜炎、炎症性肺病、慢性阻塞性肺病、阿尔茨海默病和癌症。
• [EN] ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS ALLOSTÉRIQUES D'EGFR ET LEURS MÉTHODES D'UTILISATION
  申请人：DANA FARBER CANCER INST INC

  公开号：WO2021252661A1

  公开（公告）日：2021-12-16

  The disclosure relates to compounds that act as allosteric inhibitors of epidermal growth factor receptor (EGFR); pharmaceutical compositions comprising the compounds; and methods of treating or preventing kinase-mediated disorders, including cancer and other proliferation diseases.

  本公开涉及作为表皮生长因子受体（EGFR）的异构抑制剂的化合物；包括该化合物的制药组合物；以及用于治疗或预防激酶介导的疾病，包括癌症和其他增殖性疾病的方法。
• Integrase Inhibitors 3
  申请人：Rhodes David Ian

  公开号：US20100009973A1

  公开（公告）日：2010-01-14

  The present invention provides a method of treatment or prophylaxis of a viral infection in a subject comprising administering to said subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative, salt or prodrug thereof. Compounds of formula (I) are also provided.

  本发明提供了一种治疗或预防受试者病毒感染的方法，包括向该受试者施用公式（I）的化合物或其药学上可接受的衍生物、盐或前药的有效量。本发明还提供了公式（I）的化合物。
• Inhibitors of the renal outer medullary potassium channel
  申请人：Pasternak Alexander

  公开号：US09056859B2

  公开（公告）日：2015-06-16

  This invention relates to compounds having structural Formula (I); and pharmaceutically acceptable salts thereof which are inhibitors of the Renal Outer Medullary Potassium (ROMK) channel (Kir 1.1). The compounds of Formula I are useful as diuretics and natriuretics and therefore are useful for the therapy and prophylaxis of disorders resulting from excessive salt and water retention, including cardiovascular diseases such as hypertension and chronic and acute heart failure.

  本发明涉及具有结构式（I）的化合物及其药学上可接受的盐，这些化合物是肾外髓质钾（ROMK）通道（Kir 1.1）的抑制剂。式I的化合物可用作利尿剂和钠利尿剂，因此可用于治疗和预防由过度盐和水潴留引起的疾病，包括心血管疾病，如高血压和慢性和急性心力衰竭。